Information  X 
Enter a valid email address

Synairgen plc (SNG)

  Print      Mail a friend       Annual reports

Wednesday 22 July, 2020

Synairgen plc

Holding(s) in Company

RNS Number : 7919T
Synairgen plc
22 July 2020
 

Synairgen plc

("Synairgen" or the "Company")

Holding(s) in Company

 

Southampton, UK , : Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, announces that it was informed on 22 July 2020 that Leonard Licht, a private investor, now holds 7,770,000 ordinary shares of 1 pence  each in the capital of the Company, representing 5.20% of the Company's issued share capital.

 

Enquiries:

Synairgen plc

+44 (0) 23 8051 2800

Richard Marsden (Chief Executive Officer)
John Ward (Finance Director)


finnCap - nominated adviser and broker

+44 (0) 20 7220 0500

Geoff Nash, Kate Bannatyne, Charlie Beeson (Corporate Finance)
Alice Lane, Manasa Patil (ECM)


Consilium Strategic Communications - financial media and investor relations adviser

+44 (0) 20 3709 5700

Mary-Jane Elliott, Sue Stuart, Olivia Manser


 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
HOLFLFIVDSIFFII

a d v e r t i s e m e n t